Evidence map›Paper›PMID 32141035›Full record

ArticleDrug delivery and translational research2020

The solid progress of nanomedicine.

João Pedro Martins, José das Neves, María de la Fuente, Christian Celia, Helena Florindo, Nazende Günday-Türeli, Amirali Popat, José Luis Santos, Flávia Sousa, Ruth Schmid and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery and translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 122 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Gefitinib-loaded starch nanoparticles for battling lung cancer: Optimization by full factorial design andSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 7 countries.

João Pedro MartinsDrug Research Program, Division of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.
José das Nevesi3S - Instituto de Investigação e Inovação em Saúde & INEB - Instituto de Engenharia Biomédica, University of Porto, Porto, Portugal.
María de la FuenteNano-Oncology Unit, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), CIBERONC, 15706, Santiago de Compostela, Spain.
Christian CeliaDepartment of Pharmacy, University of Chieti - Pescara "G. d'Annunzio", Chieti, Italy.
Helena FlorindoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Nazende Günday-TüreliMyBiotech GmbH, Industriestr. 1B, 66802, Überherrn, Germany.
Amirali PopatSchool of Pharmacy, The University of Queensland, Brisbane, 4102, Australia.
José Luis SantosDosage Form Design and Development, AstraZeneca, Gaithersburg, MD, USA.
Flávia Sousai3S - Instituto de Investigação e Inovação em Saúde & INEB - Instituto de Engenharia Biomédica, University of Porto, Porto, Portugal.
Ruth SchmidDepartment of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim, Norway.
Joy WolframDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL, USA.
Bruno Sarmentoi3S - Instituto de Investigação e Inovação em Saúde & INEB - Instituto de Engenharia Biomédica, University of Porto, Porto, Portugal.
Hélder A SantosDrug Research Program, Division of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland. helder.santos@helsinki.fi.
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTUniversity of Helsinki · FIAstraZeneca (United States) · USInstituto de Investigación Sanitaria de Santiago · ESSINTEF · NOUniversity of Chieti-Pescara · ITUniversity of Lisbon · PTUniversity of Queensland · AUWinnMed · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This commentary article conveys the views of the board of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society regarding the decision of the United States National Cancer Institute (NCI) in halting funding for the Centers of Cancer Nanotechnology Excellence (CCNEs), and the subsequent editorial articles that broadened this discussion. Graphical abstract.

Indexed as

Focus GroupsHumansNanomedicineNational Cancer Institute (U.S.)NeoplasmsUnited StatesCancer therapyClinical translationNanomedicineNanotechnologyReproducibility

Identifiers

PMID32141035
PMCPMC7228908
OpenAlexW3010491497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.